Unknown statusInterventionalPhase 2Updated May 3, 2022
Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment | NCT00370201 | Trialant
Unknown statusInterventionalPhase 3Updated Oct 9, 2006
Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
ClinicalTrials.gov ID
NCT00370201
Lead Sponsor
Shahid Beheshti University of Medical SciencesOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Oct 9, 2006Estimated
Start Date
Mar 2004
Completion Date
Aug 2006
Brief Summary
This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment
Rhegmatogenous Retinal Detachment
colchicine
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Rhegmatogenous retinal detachment
Exclusion Criteria:
PVR grade C
Duration of retinal detachment ≥ one month
History of cataract surgery
History of RD surgery
Primary Purpose
Treatment
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
Double
No central contacts
There are no central contacts for this study.
Hamid Ahmadieh,MD
Tehran, Tehran Province 16666, Iran
Lead Sponsor
Shahid Beheshti University of Medical SciencesOTHER